A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution  Talia M. Muram, John H. Sloan, Jana S. Chain, Wendy J. Komocsar, Bruce I. Meiklejohn, Andrew Blauvelt, Kim Papp, Michael P. Heffernan, Yue-Wei Qian, Robert J. Konrad  Journal of Investigative Dermatology  Volume 136, Issue 7, Pages 1513-1515 (July 2016) DOI: 10.1016/j.jid.2016.01.040 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Sensitivity of ACE assay compared with MSD bridging assay. Affinity-purified anti-ixekizumab antibody from monkeys or humans was spiked into normal human serum at concentrations ranging from 2-2000 ng/m. Samples were analyzed on the ACE and MSD bridging assays, with results shown as the mean ± SEM (n = 2). The MSD bridging assay reports in ECL units (ECLU), while the ACE assay generates an OD450 readout. Ab, antibody; ACE, affinity capture elution; ECLU, electrochemiluminescent units; MSD, Meso Scale Discovery; MSDB, Meso Scale Discovery bridging; OD450, optical density at 450 nanometers. Journal of Investigative Dermatology 2016 136, 1513-1515DOI: (10.1016/j.jid.2016.01.040) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Drug tolerance of ACE assay compared with MSD bridging assay. Affinity-purified anti-ixekizumab antibody from monkeys or humans was spiked into normal human serum at a concentration of 500 ng/ml. Samples were also spiked with concentrations of ixekizumab ranging from 0.1–500.0 μg/ml and analyzed on the ACE and MSD bridging assays. Results are shown as the mean ± standard error of the mean (n = 2). The MSD bridging assay is reported in ECLUs, whereas the ACE assay generates an OD450 readout. Ab, antibody; ACE, affinity capture elution; ECLU, electrochemiluminescent units; MSD, Meso Scale Discovery; MSDB, Meso Scale Discovery bridging; OD450, optical density at 450 nanometers. Journal of Investigative Dermatology 2016 136, 1513-1515DOI: (10.1016/j.jid.2016.01.040) Copyright © 2016 The Authors Terms and Conditions